New in 2022: Solvias acquires Cergentis to strengthen biologics and cell & Gene therapy capabilities

Solvias expands testing solutions to support development of safe and effective advanced therapies

New in 2022: Solvias acquires Cergentis to strengthen biologics and cell & Gene therapy capabilities

New in 2022: Solvias acquires Cergentis to strengthen biologics and cell & Gene therapy capabilities

Solvias, one of the world’s leading independent pharmaceutical, biotech and medical device industries, announced on Tuesday that it acquired Utrecht, Netherlands-based Cergentis. The acquisition strengthens Solvias platform of biologics and cell & gene therapy (CGT) testing solutions.

According to pharmaceutical market intelligence provider, Evaluate, global sales of cell and gene therapies are expected to accelerate at a 63 percent compound annual growth rate (CAGR) through 2026. As more researchers hold on to emerging genetic engineering techniques to develop complex, novel medicines, they require sophisticated solutions to examine their well-being and efficiency.

With the inclusion of Cergentis, Solvias supports the rolling number of global pharmaceutical, biotech, manufacturing, and contract development organizations developing genetically engineered therapies with an extended platform of testing services emphasised by:

The Chief Executive Officer at Solvias, Archie Cullen stated that the company has relentlessly focused on ensuring the safety of new therapies in development. Cergentis is a foundation for acquisition with their solutions supporting complex and emerging therapies. He added that they would continue to pursue strategic acquisitions that add specialized capabilities to their offering and advance their goal of being a forerunner in the pharmaceutical manufacturing industry.

Joris Schuurmans, the Chief Executive Officer of Cergentis added that they were excited to be a part of a global leader that complements their scientific expertise, customer service and innovation. The two companies share a deep commitment to provide customers with the highest quality solutions and support to ensure that their products safely reach the people who need them the most.

Joris Schuurmans will join the Solvias leadership team and continue to lead operations for Cergentis, with immediate effect.

Cergentis marks Solvias’ second acquisition since associating with health care investors Water Street Healthcare Partners and JLL Partners in 2020.The company has enlisted business leaders to join its board and started a program to notably expand and upgrade its information technology platform and infrastructure to support its plans for international expansion.

About Cergentis

Cergentis is a trusted genomics-focused biotechnology company providing in-house solutions and services based on its proprietary genomic analysis platform to all leading biopharmaceutical companies and renowned research organizations. With widely recognized and published genetic analyses, the company harnesses a global customer base in the QC and characterization of genetically engineered models, biopharmaceutical cell line development, and cell- and gene therapy products. By serving to eliminate risk of minimizing time-to-clinic, R&D program decisions, supporting patient safety and providing objective genomic evidence for regulators, Cergentis aims to support biopharmaceutical medicine development programs globally.

About Solvias AG

 Solvias is a global leader in manufacturing, pharmaceutical, biotech, contract research, development and for material science and cosmetic industries. Leveraging on twenty years of scientific expertise, Solvias delivers scalable and flexible  manufacturing and analytical solutions that ensure the sustainability of pharmaceutical and medical device products across their life cycle. Solvias is headquartered in Kaiseraugst near Basel, Switzerland, and its laboratories operate to the highest standards and in accordance with ISO, GMP, GLP and FDA guidelines.

Exit mobile version